Perioperatoire MedicineOPIOID CITY FRNCT07659730
Evaluation of a Structured Hospital-Community Care Follow-up Based on Perceived Quality of Care After Surgery, Aimed at Reducing Persistent Opioid Use in Primary Care: a Pragmatic Randomized Controlled Trial
A study testing Patient-Reported Outcomes-based perioperative follow-up (QoR-15 focus) in people with Perioperatoire Medicine and Surgery, run by University Hospital, Strasbourg, France.
Trial summary
The OPTIMISTE program is based on a structured postoperative follow-up centered on patients' subjective perception of recovery using validated Patient Reported Outcome Measures (PROMs), including the mQoR-15f score. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Perioperatoire Medicine, Surgery
- What is being tested?
- Patient-Reported Outcomes-based perioperative follow-up (QoR-15 focus)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 772 participants
- Where
- No sites listed yet
- Study dates
- 2 Jul 2026to 1 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female
- Adult patient, with no upper age limit
- Undergoing scheduled or unscheduled surgery in a center participating in the research
- Subject affiliated to a social health insurance scheme
- Subject able to understand the objectives and risks related to the research and to give informed consent, dated and signed
Who cannot join
- Inability to administer the mQoR-15f questionnaire (cognitive disorders, language barrier)
- Patient who has already received previous follow-up by the OPTIMISTE team
- Patient enrolled in a therapeutic trial that may affect post-operative recovery quality.
- Pregnant or breastfeeding woman
- Inability to provide the subject with informed information (subject in an emergency situation, difficulties in understanding, etc.)
- Subject under legal protection, guardianship or curatorship
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The OPTIMISTE program is based on a structured postoperative follow-up centered on patients' subjective perception of recovery using validated Patient Reported Outcome Measures (PROMs), including the mQoR-15f score. Follow-up is delivered by specifically trained nurses and embedded in a decompartmentalized care model combining in-person and remote interactions, integrating hospital teams and primary care professionals within a coordinated pathway.
OPTIMISTE was recently evaluated in a multicenter randomized controlled trial, the SUPPORT study (NCT06182254), which included 280 patients. The study demonstrated a significant impact of PROM-based follow-up on perceived recovery at postoperative day 35, and more importantly, an approximately 50% reduction in the proportion of patients with persistent opioid use at that time point. Although this was a secondary endpoint, the findings suggest that active postoperative monitoring centered on patient-reported outcomes and rapidly relayed to community care providers represents a major lever for preventing opioid misuse after surgery.
Read more
However, these results require further confirmation and refinement. First, the effect on persistent opioid consumption needs to be validated as a primary endpoint. Second, despite the benefit observed, more than 12% of patients in the intervention group still exhibited persistent opioid use five weeks after surgery, compared with 21% in the control group. This residual persistence, although reduced, remains clinically concerning and indicates that the current OPTIMISTE model does not yet fully prevent unanticipated prolonged opioid exposure.
The hypothesis of the present protocol is that the effectiveness of OPTIMISTE in reducing postoperative persistent opioid use can be strengthened through earlier, more individualized and primary-care-driven management. This enhancement relies on better mobilization of community healthcare professionals - general practitioners, community nurses and pharmacists - supported by digital health tools and reinforced coordination channels such as secure platforms, teleconsultations and structured transmission of PROM scores.
By systematically integrating primary care providers into longitudinal postoperative follow-up guided by PROMs, the protocol aims to improve therapeutic responsiveness, reduce unjustified prolonged prescriptions and promote early tapering when clinically appropriate. The objective is to optimize hospital-community coordination in order to amplify the impact of the OPTIMISTE pathway on patient-perceived recovery and opioid stewardship.
Ultimately, this research seeks to demonstrate that strengthening the role of primary care, combined with fine-grained assessment of patient-reported recovery, represents an effective, ethical and scalable strategy to improve the quality, safety and efficiency of postoperative care pathways while sustainably reducing persistent opioid use at both individual and population levels.
Read the detailed description
The study is an open-label, multicenter, randomized controlled trial comparing two groups:
- Control group Participants in the control group receive the usual conventional postoperative follow-up, notably by the surgeon and the attending physician.
- Experimental group
In addition to the usual conventional follow-up, participants in the experimental group benefit from a comprehensive, closely coordinated care pathway between hospital and primary care, based on active collaboration with community healthcare professionals. This enhanced follow-up includes:
- Establishment of a personalized recovery trajectory,
- Early identification of any delay or difficulty in the recovery process,
- Adaptation of follow-up and adjustment of the care pathway in response to potential complications,
- Generation of a personalized report transmitted to the general practitioner to facilitate ongoing care,
- Simplified access to specialist consultations if clinically required, and
- a pharmaceutical consultation with the community pharmacist to optimize and secure medication use.
The program also integrates specially trained nurses who assess patients' health status according to their own perception (OPTIMISTE follow-up). From postoperative day 14 onward, if a risk of persistent opioid use is identified, a coordinated intervention between hospital and community care is initiated to ensure timely therapeutic adjustments, promote appropriate tapering, and prevent unjustified prolonged opioid exposure.
- Conditions
- Perioperatoire Medicine, Surgery
- Being tested
- Patient-Reported Outcomes-based perioperative follow-up (QoR-15 focus)
- Keywords
- Perioperative, Surgery, Patient Reported Outcomes Mesuares (PROMs), persistent opioid use
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patient-Reported Outcomes-based perioperative follow-up (QoR-15 focus)Other
Tip: Ensure that this name matches the name used in the associated Arm Description.
Patient Reported Outcomes based perioperative follow-up.
Description - Patient-Reported Outcomes-based perioperative follow-up (QoR-15 focus) The Patient-Reported Outcomes-based perioperative follow-up is a patient-centered approach that evaluates postoperative recovery using standardized questionnaires completed directly by the patient. This method highlights the patient's own perception of recovery-covering physical comfort, emotional state, independence, and pain control-rather than relying solely on clinical or physiological parameters.
The Quality of Recovery-15 (QoR-15) score is a validated, short-form tool designed to measure the quality of postoperative recovery from the patient's perspective. It consists of 15 items covering five key dimensions:
- Physical comfort (pain, nausea, general well-being)
- Emotional state (anxiety, depression, feeling of support)
- Psychological support
| Study group | Role | What they receive |
|---|---|---|
| Experimental group | Experimental | Participants in the experimental group receive, in addition to standard postoperative follow-up, a structured PROMs-based OPTIMISTE program assessing health status with the mQoR-15f at multiple predefined time points: preoperatively, and on postoperative days 1, 3, 14, and 28. Assessments are conducted by specially trained nurses, in hospital or via phone once patients return to primary care, and aim to detect incomplete recovery and persistent opioid use early, prevent prolonged pain, and strengthen coordination between hospital and community care providers.
From postoperative day 14, if a risk of persistent opioid use is identified, a coordinated hospital-community intervention is triggered. This includes:
1. A structured report to the patient's general practitioner, co-designed with participating GPs, summarizing surgical details, PROMs-based recovery evolution, type of persistent opioid use, proposed tapering strategy, and hospital care recommendations. This report is shared via t Receives: Other: Patient-Reported Outcomes-based perioperative follow-up (QoR-15 focus) |
| Control group | Active comparator | Perioperative follow up will include routine follow-up by the perioperative team including the surgical team without the intervention of the dedicated PROMs based interviews team.
The control group, on the other hand, will receive standard follow-up coordinated by the surgeon and in collaboration with the primary care physician and other community healthcare professionals, without intervention by a nurse practitioner (NP) or registered nurse (RN) and without PROMs-based follow-up.
(modified QoR-15f score will be administered to all patients at visit 0 and Day 35 and Day 90). Receives: Other: Patient-Reported Outcomes-based perioperative follow-up (QoR-15 focus) |
What is being measured
The primary outcome is the main question the study is designed to answer.
The main objective is to Evaluate the impact of a structured hospital-community follow-up on persistent opioid use in primary care 90 days after a surgical procedure.
Persistent opioid use at postoperative day 90 is defined as the use of a weak or strong opioid at least once per week. This definition includes all weak opioids (WHO class 2) and strong opioids (WHO class 3), regardless of dosage form (e.g., immediate-release or extended-release) or route of administration (e.g., oral or transdermal).
Measured: between baseline consultation and "day 90"
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2026
- Study start2 Jul 2026 (estimated)
- Primary completion1 Dec 2029 (estimated)
- Study completion1 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Perioperatoire MedicineStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study is an open-label, multicenter, randomized controlled trial comparing two groups
- Masking
- None (open label)
- Enrolment
- 772 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07659730
- Sponsor's protocol ID
- RC26_0018
- Other IDs
- 2025-A02738-41
- Acronym
- OPIOID CITY FR
- Status last verified
- Jun 2026
- First submitted
- 15 Jun 2026
- Last updated
- 22 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of a Structured Hospital-Community Care Follow-up Based on Perceived Quality of Care After Surgery, Aimed at Reducing Persistent Opioid Use in Primary Care: a Pragmatic Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07659730
- Acronym / sponsor ID
- OPIOID CITY FR / RC26_0018
- Conditions
- Perioperatoire Medicine, Surgery
- Keywords
- Perioperative, Surgery, Patient Reported Outcomes Mesuares (PROMs), persistent opioid use
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 772 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 2 Jul 2026 (estimated)
- Primary completion
- 1 Dec 2029 (estimated)
- Study completion
- 1 Dec 2029 (estimated)
- First posted
- 22 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The OPTIMISTE program is based on a structured postoperative follow-up centered on patients' subjective perception of recovery using validated Patient Reported Outcome Measures (PROMs), including the mQoR-15f score. Follow-up is delivered by specifically trained nurses and embedded in a decompartmentalized care model combining in-person and remote interactions, integrating hospital teams and primary care professionals within a coordinated pathway.
OPTIMISTE was recently evaluated in a multicenter randomized controlled trial, the SUPPORT study (NCT06182254), which included 280 patients. The study demonstrated a significant impact of PROM-based follow-up on perceived recovery at postoperative day 35, and more importantly, an approximately 50% reduction in the proportion of patients with persistent opioid use at that time point. Although this was a secondary endpoint, the findings suggest that active postoperative monitoring centered on patient-reported outcomes and rapidly relayed to community care providers represents a major lever for preventing opioid misuse after surgery.
However, these results require further confirmation and refinement. First, the effect on persistent opioid consumption needs to be validated as a primary endpoint. Second, despite the benefit observed, more than 12% of patients in the intervention group still exhibited persistent opioid use five weeks after surgery, compared with 21% in the control group. This residual persistence, although reduced, remains clinically concerning and indicates that the current OPTIMISTE model does not yet fully prevent unanticipated prolonged opioid exposure.
The hypothesis of the present protocol is that the effectiveness of OPTIMISTE in reducing postoperative persistent opioid use can be strengthened through earlier, more individualized and primary-care-driven management. This enhancement relies on better mobilization of community healthcare professionals - general practitioners, community nurses and pharmacists - supported by digital health tools and reinforced coordination channels such as secure platforms, teleconsultations and structured transmission of PROM scores.
By systematically integrating primary care providers into longitudinal postoperative follow-up guided by PROMs, the protocol aims to improve therapeutic responsiveness, reduce unjustified prolonged prescriptions and promote early tapering when clinically appropriate. The objective is to optimize hospital-community coordination in order to amplify the impact of the OPTIMISTE pathway on patient-perceived recovery and opioid stewardship.
Ultimately, this research seeks to demonstrate that strengthening the role of primary care, combined with fine-grained assessment of patient-reported recovery, represents an effective, ethical and scalable strategy to improve the quality, safety and efficiency of postoperative care pathways while sustainably reducing persistent opioid use at both individual and population levels.
Detailed description
The study is an open-label, multicenter, randomized controlled trial comparing two groups:
- Control group Participants in the control group receive the usual conventional postoperative follow-up, notably by the surgeon and the attending physician.
- Experimental group
In addition to the usual conventional follow-up, participants in the experimental group benefit from a comprehensive, closely coordinated care pathway between hospital and primary care, based on active collaboration with community healthcare professionals. This enhanced follow-up includes:
- Establishment of a personalized recovery trajectory,
- Early identification of any delay or difficulty in the recovery process,
- Adaptation of follow-up and adjustment of the care pathway in response to potential complications,
- Generation of a personalized report transmitted to the general practitioner to facilitate ongoing care,
- Simplified access to specialist consultations if clinically required, and
- a pharmaceutical consultation with the community pharmacist to optimize and secure medication use.
The program also integrates specially trained nurses who assess patients' health status according to their own perception (OPTIMISTE follow-up). From postoperative day 14 onward, if a risk of persistent opioid use is identified, a coordinated intervention between hospital and community care is initiated to ensure timely therapeutic adjustments, promote appropriate tapering, and prevent unjustified prolonged opioid exposure.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The study is an open-label, multicenter, randomized controlled trial comparing two groups
| Arm | Type | Receives |
|---|---|---|
| Experimental group | Experimental | Other: Patient-Reported Outcomes-based perioperative follow-up (QoR-15 focus)Participants in the experimental group receive, in addition to standard postoperative follow-up, a structured PROMs-based OPTIMISTE program assessing health status with the mQoR-15f at multiple predefined time points: preoperatively, and on postoperative days 1, 3, 14, and 28. Assessments are conducted by specially trained nurses, in hospital or via phone once patients return to primary care, and aim to detect incomplete recovery and persistent opioid use early, prevent prolonged pain, and strengthen coordination between hospital and community care providers. From postoperative day 14, if a risk of persistent opioid use is identified, a coordinated hospital-community intervention is triggered. This includes: 1. A structured report to the patient's general practitioner, co-designed with participating GPs, summarizing surgical details, PROMs-based recovery evolution, type of persistent opioid use, proposed tapering strategy, and hospital care recommendations. This report is shared via t |
| Control group | Active comparator | Other: Patient-Reported Outcomes-based perioperative follow-up (QoR-15 focus)Perioperative follow up will include routine follow-up by the perioperative team including the surgical team without the intervention of the dedicated PROMs based interviews team. The control group, on the other hand, will receive standard follow-up coordinated by the surgeon and in collaboration with the primary care physician and other community healthcare professionals, without intervention by a nurse practitioner (NP) or registered nurse (RN) and without PROMs-based follow-up. (modified QoR-15f score will be administered to all patients at visit 0 and Day 35 and Day 90). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Male or female
- Adult patient, with no upper age limit
- Undergoing scheduled or unscheduled surgery in a center participating in the research
- Subject affiliated to a social health insurance scheme
- Subject able to understand the objectives and risks related to the research and to give informed consent, dated and signed
Key exclusion criteria (6 listed)
- Inability to administer the mQoR-15f questionnaire (cognitive disorders, language barrier)
- Patient who has already received previous follow-up by the OPTIMISTE team
- Patient enrolled in a therapeutic trial that may affect post-operative recovery quality.
- Pregnant or breastfeeding woman
- Inability to provide the subject with informed information (subject in an emergency situation, difficulties in understanding, etc.)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patient-Reported Outcomes-based perioperative follow-up (QoR-15 focus)Tip: Ensure that this name matches the name used in the associated Arm Description. Patient Reported Outcomes based perioperative follow-up. Description - Patient-Reported Outcomes-based perioperative follow-up (QoR-15 focus) The Patient-Reported Outcomes-based perioperative follow-up is a patient-centered approach that evaluates postoperative recovery using standardized questionnaires completed directly by the patient. This method highlights the patient's own perception of recovery-covering physical comfort, emotional state, independence, and pain control-rather than relying solely on clinical or physiological parameters. The Quality of Recovery-15 (QoR-15) score is a validated, short-form tool designed to measure the quality of postoperative recovery from the patient's perspective. It consists of 15 items covering five key dimensions: 1. Physical comfort (pain, nausea, general well-being) 2. Emotional state (anxiety, depression, feeling of support) 3. Psychological support | Other | Control group, Experimental group |
Primary outcome
The main objective is to Evaluate the impact of a structured hospital-community follow-up on persistent opioid use in primary care 90 days after a surgical procedure.
Time frame: between baseline consultation and "day 90"
Persistent opioid use at postoperative day 90 is defined as the use of a weak or strong opioid at least once per week. This definition includes all weak opioids (WHO class 2) and strong opioids (WHO class 3), regardless of dosage form (e.g., immediate-release or extended-release) or route of administration (e.g., oral or transdermal).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2026.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Patient-Reported Outcomes-based perioperative follow-up (QoR-15 focus) in people with Perioperatoire Medicine and Surgery, run by University Hospital, Strasbourg, France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Monia BEN HADJ HAMED (+33388616711, monia.ben-hadj-hamed@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The main objective is to Evaluate the impact of a structured hospital-community follow-up on persistent opioid use in primary care 90 days after a surgical procedure. (time frame: between baseline consultation and "day 90"). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.